10:04 AM EDT, 10/30/2024 (MT Newswires) -- AnaptysBio ( ANAB ) shares were down almost 22% in recent Wednesday trading after Eli Lilly ( LLY ) said it is removing arthritis drug peresolimab from its pipeline.

AnaptysBio ( ANAB ) is developing rosnilimab, an arthritis treatment that is similar to peresolimab, according to media reports.

AnaptysBio ( ANAB ) previously said on Aug. 5 in its Q2 earnings release that top-line results are expected in Q1 2025 for a phase 2b trial to treat rheumatoid arthritis with rosnilimab.

Price: 24.17, Change: -6.64, Percent Change: -21.54